United Therapeutics Corporation reported a decrease in quarterly net revenue by 18% to $311 million compared to the prior year, primarily due to a $43.6 million decrease in purchases of treprostinil-based products by a U.S. distributor adjusting inventory levels.
Full year net revenue growth of 3% excluding Adcirca.
Company expects 2020 full year net revenue growth.
INCREASE study of Tyvaso in PH-ILD met primary and secondary endpoints.
Remunity system cleared by FDA for pharmacy-filled use; launch expected by July 2020.
The company anticipates growth in net revenue over 2019 levels due to the expanded Orenitram label and the expected launch of Remunity.
Analyze how earnings announcements historically affect stock price performance